Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects

Allergan

Status and phase: Completed; Phase 4

Conditions: Eyelash Hypotrichosis

Treatments: Drug: bimatoprost 0.03%

Study type: Interventional

Funder types: Industry

Identifiers

NCT01229423

LAT-KOR-01

Details and patient eligibility

About

This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.

Enrollment: 62 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eyelash prominence assessment of minimal or moderate
• Of Korean ethnicity

Exclusion criteria

• Any eye disease or abnormality
• Any ocular surgery or use of any eyelash extension or eyelash growth products within 3 months
• Any permanent eyeliner within 5 years
• Eyelash implants of any kind
• Eyelash tint or dye application within 2 months
• Use of any treatment that may affect hair growth within 6 months

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

62 participants in 1 patient group

LATISSE®

Experimental group

Description:

bimatoprost 0.03% (LATISSE®)

Treatment:

Drug: bimatoprost 0.03%